Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Open-Label Study to Evaluate the Safety of QM1114-DP for the Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines

NCT04225260 is registered in ClinicalTrials.gov with Galderma R&D as lead sponsor.

NCT NCT04225260
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04225260 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Open-Label Study to Evaluate the Safety of QM1114-DP for the Long-term Treatment of Moderate to Severe Glabellar Lines and Lateral Canthal Lines
Lead sponsor
Galderma R&D
Phase
Phase 3
Overall status
Completed
Start date
January 27, 2020
Completion date
May 21, 2021
Enrollment
902 (actual)
Sites
30

Conditions

As the registry lists them; a condition with its own page is linked.

glabellar lines, lateral canthal lines